Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial
- 27 September 2006
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 29 (1), 91-97
- https://doi.org/10.1183/09031936.00029206
Abstract
Respiratory syncytial virus (RSV) bronchiolitis is the most common lower respiratory tract infection in infancy. To date, there is no effective therapy for RSV bronchiolitis. In order to investigate the efficacy of clarithromycin in the treatment of RSV bronchiolitis, the present authors conducted a randomised, double-blind, placebo-controlled trial comparing clarithromycin with placebo in 21 infants with a diagnosis of RSV bronchiolitis. The infants were randomised to receive clarithromycin or placebo daily for 3 weeks. Levels of interleukin (IL)-4, IL-8, eotaxin, and interferon-γ were determined in plasma, before and after treatment, using ELISA. Six months after treatment, parents were surveyed as to whether their child had experienced wheezing within the previous 6 months. Treatment with clarithromycin was associated with a statistically significant reduction in the length of hospital stay, the duration of need for supplemental oxygen and the need for β2-agonist treatment. There were significant decreases in plasma IL-4, IL-8 and eotaxin levels after 3 weeks of treatment with clarithromycin. Readmission to the hospital within 6 months after discharge was significantly lower in the clarithromycin group. In conclusion, clarithromycin has statistically significant effects on the clinical and laboratory findings in respiratory syncytial virus bronchiolitis. Therefore, clarithromycin treatment may be helpful in reducing the short-term effects of respiratory syncytial virus bronchiolitis.Keywords
This publication has 24 references indexed in Scilit:
- Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local Th2-like responseJournal of Allergy and Clinical Immunology, 2005
- Neutrophil‐mediated inflammation in respiratory syncytial viral bronchiolitisPediatrics International, 2005
- Respiratory viruses: do they protect from or induce asthma?Allergy, 2002
- Steroids Fail to Down-Regulate Respiratory Syncytial Virus-Induced IL-8 Secretion in InfantsPediatric Research, 2002
- Clarithromycin Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial CellsAntimicrobial Agents and Chemotherapy, 2001
- Anti-inflammatory activity of macrolides: a new therapeutic potential?Journal of Antimicrobial Chemotherapy, 1998
- Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen.JCI Insight, 1997
- Asthma and Wheezing in the First Six Years of LifeNew England Journal of Medicine, 1995
- Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection.Archives of Disease in Childhood, 1994
- Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neotrophilsJournal of Antimicrobial Chemotherapy, 1989